David Heredia/drdavidherediav.com
Aug 28, 2025, 15:55
David Heredia: LEOPARD Study Highlights Early NSCLC Recurrence
David Heredia, Head of the Oncology Department at Punta Medica, shared a post on X:
”In the real-world LEOPARD study (stage III NSCLC): 56% recurred after chemoradiotherapy plus Durvalumab.
Timing:
- 53% within first 12 cycles,
- 25% between 12–24,
- 22% after 24 cycles.
72% had oligorecurrence.
Most relapses were limited and early, suggesting opportunity for local approaches.”
Title: Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Authors: P. Ciammella, F. Iori, P. Borghetti, M. Galaverni, E. Alì, M. Tiseo, M. Pagano, M. Sepulcri, V. Scotti, N. Giaj Levra, M. Marcenaro, N. Simoni, V. Nardone, A. Bottin, S. Cozzi, A. Bruni
You can read the Full Article on Lung Cancer.
More posts featuring David Heredia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 28, 2025, 15:56
Aug 28, 2025, 15:55
Aug 28, 2025, 15:53
Aug 28, 2025, 15:48
Aug 28, 2025, 15:40
Aug 28, 2025, 15:28
Aug 28, 2025, 15:27